MA31707B1 - Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 - Google Patents

Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1

Info

Publication number
MA31707B1
MA31707B1 MA32702A MA32702A MA31707B1 MA 31707 B1 MA31707 B1 MA 31707B1 MA 32702 A MA32702 A MA 32702A MA 32702 A MA32702 A MA 32702A MA 31707 B1 MA31707 B1 MA 31707B1
Authority
MA
Morocco
Prior art keywords
dgat1
benzimidazole
indole derivatives
oxadiazole
oxazole
Prior art date
Application number
MA32702A
Other languages
Arabic (ar)
English (en)
Inventor
Young-Shin Kwak
Gary Mark Coppola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31707B1 publication Critical patent/MA31707B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention porte sur des dérivés de benzimidazole et d'indole substitués par de l'oxadiazolyle utiles pour traiter des états ou des troubles associés à l'activité de la dgat1 chez l'animaux, en particulier l'être humain.
MA32702A 2007-09-28 2010-03-17 Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 MA31707B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97606407P 2007-09-28 2007-09-28
PCT/EP2008/062900 WO2009040410A1 (fr) 2007-09-28 2008-09-26 Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1

Publications (1)

Publication Number Publication Date
MA31707B1 true MA31707B1 (fr) 2010-09-01

Family

ID=39971086

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32702A MA31707B1 (fr) 2007-09-28 2010-03-17 Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1

Country Status (27)

Country Link
US (2) US7879850B2 (fr)
EP (1) EP2205595B1 (fr)
JP (1) JP5675359B2 (fr)
KR (1) KR101616133B1 (fr)
CN (1) CN101932576B (fr)
AR (1) AR066169A1 (fr)
AU (1) AU2008303541B2 (fr)
BR (1) BRPI0817272A2 (fr)
CA (1) CA2701053C (fr)
CL (1) CL2008002871A1 (fr)
CO (1) CO6251263A2 (fr)
CR (1) CR11261A (fr)
CU (1) CU20100049A7 (fr)
EA (1) EA019347B1 (fr)
EC (1) ECSP10010051A (fr)
ES (1) ES2525703T3 (fr)
IL (1) IL203797A (fr)
MA (1) MA31707B1 (fr)
MX (1) MX2010003264A (fr)
MY (1) MY151551A (fr)
NZ (1) NZ583285A (fr)
PE (1) PE20090774A1 (fr)
TN (1) TN2010000096A1 (fr)
TW (1) TWI429642B (fr)
UA (1) UA99305C2 (fr)
WO (1) WO2009040410A1 (fr)
ZA (1) ZA201000829B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
AU2007266796B2 (en) 2006-05-30 2011-02-10 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (fr) * 2008-03-10 2009-09-17 Novartis Ag Procédé d’accroissement de phosphatidyl-choline des cellules par l’inhibition de la dgat1
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
CN102781915A (zh) 2009-12-31 2012-11-14 皮拉马尔有限公司 二酰甘油酰基转移酶抑制剂
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
WO2012044567A2 (fr) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Dérivés d'imidazole
WO2012064569A1 (fr) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Dérivés d'imidazole
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
WO2013074387A1 (fr) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Dérivés d'imidazole
WO2013169648A1 (fr) 2012-05-07 2013-11-14 Novartis Ag Combinaisons pharmaceutiques comprenant un inhibiteur de dgat1 et un médicament abaissant la teneur en triglycérides
JP6099753B2 (ja) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
EP3492474B1 (fr) * 2012-11-23 2021-08-11 GlaxoSmithKline LLC Intermediares pour la procuction d'inhibiteurs de diacylglycérol acyltransférase
WO2014081996A1 (fr) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Nouveaux composés en tant qu'inhibiteurs de diacylglycérol acyltransférase
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CN103087045B (zh) * 2013-01-11 2015-08-12 上海交通大学 一种苯并咪唑类杂环化合物、药物组合物及其用途
CN104672144A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途
CN104610152A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼类gpr119激动剂、制备方法及其用途
PE20210158A1 (es) 2018-03-16 2021-01-26 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estrenimiento grave
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
WO2020110008A1 (fr) 2018-11-27 2020-06-04 Novartis Ag Composés pentamères cycliques servant d'inhibiteurs de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) pour le traitement d'un trouble métabolique
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2023084449A1 (fr) 2021-11-12 2023-05-19 Novartis Ag Dérivés diaminocyclopentylpyridines pour le traitement d'une maladie ou d'un trouble
CN117466863B (zh) * 2022-07-20 2026-03-24 盛睿泽华医药科技（苏州）有限公司 含芳香族取代基的苯并咪唑化合物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0882718B1 (fr) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
WO2002072549A1 (fr) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Heterocycles fonctionnalises en tant que modulateurs de la fonction du recepteur de chimiokines et procedes de mise en oeuvre
HUP0401748A3 (en) 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
WO2008011131A2 (fr) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Composés amidés
EP1562956A4 (fr) 2002-11-22 2007-10-10 Japan Tobacco Inc Heterocycles contenant de l'azote bicyclique fusionne
WO2004052848A1 (fr) 2002-12-11 2004-06-24 Eli Lilly And Company Nouveaux antagonistes du récepteur de l'hormone de concentration en mélanine
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
JP3878625B2 (ja) * 2003-06-20 2007-02-07 松下電器産業株式会社 振幅調整回路、モータ駆動制御装置、振幅調整方法、及びモータ駆動制御方法
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005013907A2 (fr) * 2003-08-07 2005-02-17 Japan Tobacco Inc. Derives de pyrrolo[1,2-b]pyridazine
WO2005035526A1 (fr) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Composes bicycliques et leur utilisation therapeutique
JP2007522219A (ja) 2004-02-12 2007-08-09 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のアミノ複素環式調節物質
WO2005108370A1 (fr) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Composés du benzène
WO2005121132A1 (fr) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Composé hétérocyclique fondu ayant un effet anti-vhc
CA2572874A1 (fr) 2004-07-02 2006-01-12 Sankyo Company Limited Derive d'uree
AU2005295453A1 (en) 2004-10-15 2006-04-27 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
EP1807396B1 (fr) 2004-10-29 2013-06-26 Merck Sharp & Dohme Corp. Composes de 2-aminopyridine utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006082952A1 (fr) 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Composé amide
MX2007013049A (es) 2005-04-19 2008-01-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de aril alquil acido para el tratamiento de la obesidad.
JP2008540485A (ja) 2005-05-10 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ジアシルグリセロールアシルトランスフェラーゼ阻害剤
CA2610188A1 (fr) * 2005-06-11 2006-12-21 Astrazeneca Ab Derives d'oxadiazole en tant qu'inhibiteurs de la diacylglycerol acyltransferase (dgat)
CA2617055A1 (fr) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
RU2385865C2 (ru) 2005-08-15 2010-04-10 Айрм Ллк Соединения и композиции в качестве миметиков тро
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
BRPI0619052A2 (pt) 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
US20080064717A1 (en) 2006-05-19 2008-03-13 Rajesh Iyengar Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
US20080015227A1 (en) 2006-05-19 2008-01-17 Kym Philip R Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
AU2007266796B2 (en) 2006-05-30 2011-02-10 Astrazeneca Ab Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
MX2008015226A (es) 2006-05-30 2008-12-12 Astrazeneca Ab Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
EP2035397A1 (fr) 2006-06-06 2009-03-18 Astra Zeneca AB Composés chimiques
JP2009539818A (ja) 2006-06-08 2009-11-19 アストラゼネカ アクチボラグ ベンゾイミダゾールおよび糖尿病の処置のためのその使用
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611507D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
WO2008011130A2 (fr) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Composés amidés
WO2008059026A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouveaux 2-(2-hydroxyphényl)benzimidazoles utilisés pour traiter l'obésité et le diabète
NZ577112A (en) 2006-11-29 2012-03-30 Abbott Lab Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme compirising substituted bicyclic pyrimidines
US20100093733A1 (en) 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en) 2007-04-20 2007-05-30 Astrazeneca Ab Chemical compounds
NZ580662A (en) 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
BRPI0810719A8 (pt) 2007-04-30 2016-03-08 Abbott Lab Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2155687A1 (fr) 2007-05-22 2010-02-24 Via Pharmaceuticals, Inc. Inhibiteurs de diacylglycérol acyltransférase
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP5443342B2 (ja) 2007-06-08 2014-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピペリジン／ピペラジン誘導体
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
ES2483898T3 (es) 2007-06-08 2014-08-08 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
EP2152270B1 (fr) 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Dérivés de piperidine/piperazine
WO2009011285A1 (fr) 2007-07-13 2009-01-22 Taisho Pharmaceutical Co., Ltd. Composés hétéroarylbenzènes
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
JP2010536839A (ja) 2007-08-17 2010-12-02 アストラゼネカ アクチボラグ 化合物９７９
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009071483A1 (fr) 2007-12-07 2009-06-11 Via Pharmaceuticals, Inc. 1-(indazol-5-yl)urées comme inhibiteurs de diacylglycérol acyltransférase
AR069802A1 (es) 2007-12-20 2010-02-17 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
WO2009119534A1 (fr) 2008-03-26 2009-10-01 第一三共株式会社 Nouveau dérivé de tétrahydroisoquinoléine
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
EP2349484A2 (fr) * 2008-07-15 2011-08-03 Novartis AG Dérivés d'hétéroaryles comme inhibiteurs de dgat1

Also Published As

Publication number Publication date
AU2008303541B2 (en) 2012-06-07
KR101616133B1 (ko) 2016-04-27
KR20100071048A (ko) 2010-06-28
CL2008002871A1 (es) 2009-05-15
TN2010000096A1 (en) 2011-09-26
PE20090774A1 (es) 2009-07-17
TWI429642B (zh) 2014-03-11
CU23901B1 (fr) 2013-06-28
CU20100049A7 (es) 2011-09-21
AU2008303541A1 (en) 2009-04-02
JP2011501735A (ja) 2011-01-13
US20090186891A1 (en) 2009-07-23
EP2205595B1 (fr) 2014-09-10
MY151551A (en) 2014-06-13
ES2525703T3 (es) 2014-12-29
MX2010003264A (es) 2010-04-01
US7879850B2 (en) 2011-02-01
CN101932576A (zh) 2010-12-29
NZ583285A (en) 2012-05-25
IL203797A (en) 2014-01-30
EA201000428A1 (ru) 2010-10-29
CR11261A (es) 2010-04-26
ECSP10010051A (es) 2010-04-30
BRPI0817272A2 (pt) 2015-06-16
UA99305C2 (ru) 2012-08-10
EP2205595A1 (fr) 2010-07-14
TW200914449A (en) 2009-04-01
CA2701053C (fr) 2016-08-23
WO2009040410A1 (fr) 2009-04-02
CO6251263A2 (es) 2011-02-21
CA2701053A1 (fr) 2009-04-02
EA019347B1 (ru) 2014-03-31
AR066169A1 (es) 2009-07-29
US8217065B2 (en) 2012-07-10
JP5675359B2 (ja) 2015-02-25
CN101932576B (zh) 2014-09-10
ZA201000829B (en) 2010-12-29
US20110077277A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
EA201000428A1 (ru) Оксадиазол- и оксазолзамещенные производные бензимидазола и индола как ингибиторы dgat1
MA30340B1 (fr) Nouveaux composes
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
UA102336C2 (uk) N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MX2009001327A (es) Compuestos de indol.
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TW200716594A (en) Substituted heteroaryl CB1 antagonists
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA30655B1 (fr) Composes organiques.
PH12014501677B1 (en) 5-membered heterocyclic amides and related compounds
ATE384058T1 (de) Thiazolderivate
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
CY1113734T1 (el) Χημικες ενωσεις
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
EP1740559A4 (fr) Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières